A fast growing spectrum of biological functions of γ-secretase in development and disease  by Jurisch-Yaksi, Nathalie et al.
Biochimica et Biophysica Acta 1828 (2013) 2815–2827
Contents lists available at ScienceDirect
Biochimica et Biophysica Acta
j ourna l homepage: www.e lsev ie r .com/ locate /bbamemReview
A fast growing spectrum of biological functions of γ-secretase in
development and disease☆
Nathalie Jurisch-Yaksi 1, Ragna Sannerud 1, Wim Annaert ⁎
Laboratory for Membrane Trafﬁcking, VIB-Center for the Biology of Disease & Department for Human Genetics (KU Leuven), Leuven, Belgium☆ This article is part of a Special Issue entitled: Intram
⁎ Corresponding author at: Laboratory for Membran
Gasthuisberg, O&N4, Rm. 7.159, Herestraat 49, B-3000
330520.
E-mail address: wim.annaert@cme.vib-kuleuven.be
1 These authors contributed equally to this work.
0005-2736/$ – see front matter © 2013 Elsevier B.V. All
http://dx.doi.org/10.1016/j.bbamem.2013.04.016a b s t r a c ta r t i c l e i n f oArticle history:
Received 7 January 2013
Received in revised form 3 April 2013
Accepted 11 April 2013
Keywords:
γ-Secretase, regulated intramembrane
proteolysis
Presenilin
APP
Notch
Alzheimerγ-secretase, which assembles as a tetrameric complex, is an aspartyl protease that proteolytically cleaves sub-
strate proteins within their membrane-spanning domain; a process also known as regulated intramembrane
proteolysis (RIP). RIP regulates signaling pathways by abrogating or releasing signaling molecules. Since the
discovery, already >15 years ago, of its catalytic component, presenilin, and even much earlier with the identi-
ﬁcation of amyloid precursor protein as its ﬁrst substrate, γ-secretase has been commonly associated with
Alzheimer's disease. However, starting with Notch and thereafter a continuously increasing number of novel
substrates, γ-secretase is becoming linked to an equally broader range of biological processes. This review
presents an updated overview of the current knowledge on the diverse molecular mechanisms and signaling
pathways controlled by γ-secretase, with a focus on organ development, homeostasis and dysfunction. This ar-
ticle is part of a Special Issue entitled: Intramembrane Proteases.
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γ-Secretase is a promiscuous di-aspartyl protease responsible for
the cleavage of a series of integral membrane proteins, almost all
being type I transmembrane proteins. To date, more than 90 proteins
have been identiﬁed as substrates among which the most notorious
2816 N. Jurisch-Yaksi et al. / Biochimica et Biophysica Acta 1828 (2013) 2815–2827areNotch andAmyloid precursor protein (APP). Interestingly,γ-secretase
emerged ﬁrst as an enigmatic enzymatic activity with the discovery of
amyloid β and APP as scientists realized at that time that proteolysis
within the transmembrane domain was required to generate this pep-
tide [1]. Now we know that γ-secretase is a multiprotein complex
consisting of presenilin (abbreviated as PSEN independently of its
origin), nicastrin (NCT), anterior-pharynx defective-1 (APH1) and
PSEN enhancer-2 (PEN2) [2–5]. Originally discovered by geneticists as
the protein products of genesmutated in families with autosomal dom-
inant Alzheimer's disease (AD), PSEN harbors the catalytic activity of
the complex ([6,7], reviewed in [8]). However, PSEN absolutely requires
the co-factors NCT, APH1 and PEN2 to form a functional γ-secretase
complex. Additionally, the γ-secretase complex is heterogenous in na-
ture due to the existence of two PSEN homologues (PSEN1 & 2) and
several APH1 isoforms. Different complexes are not only present in dif-
ferent tissues [9–11]; they have aswell heterogeneous biochemical and
physiological properties [12,13]. However, little is known with respect
to the cell biology of these complexes and how (or whether) they
might contribute to substrate and/or cleavage speciﬁcity [14]. In addi-
tion, PSEN also functions outside the γ-secretase complex, for instance,
in vesicular trafﬁcking, Ca2+ homeostasis, β-catenin stabilization and
cell adhesion [5,15].
γ-Secretase created thus far a tremendous attraction through its
intimate involvement in the pathophysiology of AD by catalyzing
the ﬁnal cleavage in the production of amyloid β peptides, thereby
overshadowing its increasing involvement in major physiological
processes during development as well as adulthood. In this review
we summarize our current knowledge not only on the function of
PSEN and γ-secretase in the broader physiological context, but also
provide an updated catalogue of mutations in γ-secretase compo-
nents discovered so far in human diseases.
2. Complex structure and formation
At least 19 transmembrane domains (TMD) contribute to the hydro-
phobicity of γ-secretase, of which nine are from PSEN and seven from
APH1. PEN2 has a hairpin-like topology containing two TMDs, whereas
NCT is the only type I transmembrane glycoprotein of the complex. The
crystal structure of an ancestral PSEN/signal peptide peptidase (SPP)
homologue has been recently revealed [16] (discussed in more detail
in the article of Mike Wolfe in this review series) and remarkably con-
ﬁrms earlier biochemical studies on its genuine 9 transmembrane
[17–19] and ring-structure topology [20]. Genetic ablation of only one
component results in mislocalization (notably retention in the endo-
plasmic reticulum (ER)), incomplete maturation and destabilization of
the remaining components, clearly indicating that inter- and intramo-
lecular interactions are crucial in the course of assembly, transport
and activation of the γ-secretase complex [14].
All γ-secretase components colocalize initially in the ER where
proper posttranslational modiﬁcations and quality control systems
ensure their correct folding and assembly. Their assembly is not a ran-
dom process but occurs sequentially and stoichiometrically and is
superimposed on transport regulation that ensures cell- and tissue-
speciﬁc levels of γ-secretase activity. Most studies agree on the initial
formation of an NCT–APH1 subcomplex as the ﬁrst step [21,22] that is
stable even in the absence of PSEN and PEN2 [23]. The formation of
this intermediate NCT–APH1 scaffold is regulated by the Golgi-to-ER
cargo receptor Rer1p (retrieval to ER 1 protein) [24]. Rer1p binds to
the same polar residues on the NCT TMD that are essential for inter-
action with APH1, and thus blocks APH1 interaction with NCT during
the early stages of γ-secretase complex assembly. Hence, Rer1p con-
trols formation of γ-secretase subcomplexes and, concomitantly, total
cellular γ-secretase levels and activity [14,24].
Thereafter, the sequence of events leading to the formation of a ma-
ture PSEN complexmay involve direct binding of the APH1–NCT scaffold
to PSEN followed by the incorporation of PEN2 [25,26]. This is thought totrigger the endoproteolysis of PSEN to formN- and C-terminal fragments
(NTF and CTF) that stably associate into heterodimers. Although both
fragments are part of the catalytic γ-secretase, endoproteolysis is not a
requirement for activity. Alternatively, theAPH1–NCTpre-complex com-
binationmay bind directly to a preformed PSEN1–PEN2 structure to gen-
erate the mature, active γ-secretase complex [23,27]. This alternative
assembly process is based on the detergent-based identiﬁcation of two
additional intermediate complexes, NCT–APH1–PSEN1 CTF and PEN2–
PSEN1 NTF; also the fact that PEN2 can bind full-length PSEN indepen-
dently of NCT and APH1 supports this view [28,29].
3. Regulated Intramembrane Proteolysis (RIP)
γ-Secretase belongs to the family of intramembrane cleaving
proteases (i-CLiPs) which contains in addition to the PSENs, the zinc
metalloprotease site-2 protease (S2P), the signal peptide peptidases
(SSP) and the rhomboid proteases. All i-CLiPs enzymatically cleave
their substrate proteins within the plane of the lipid bilayer in a process
termed regulated intramembrane proteolysis (RIP)([30,31]). With the
exception of rhomboid proteases, RIP requires the initial ectodomain
shedding of the substrate. Hence, the magnitude of RIP depends on
the rate-limiting regulation of these shedding enzymes. Ectodomain
shedding can be constitutive but it may also be induced by several stim-
uli such as ligand binding, protein kinase C (PKC) activation by phorbol
esters or Ca2+ inﬂux. The initial ectodomain shedding in γ-secretase-
associated RIP is essentially carried out by either of two protease fami-
lies, i.e. members of the ‘α-disintegrin and metalloprotease’ (ADAM)
family commonly referred to as α-secretases (for review see [32]) and
the aspartyl proteases BACE1 and BACE2 also called β-secretase [33].
The shedding results in the release of a soluble ectodomain into the ex-
tracellular environment and generation of a truncated membrane-
associated carboxyl terminal fragment (CTF). The CTF is in turn cleaved
by the i-CLiP that releases the intracellular domains (ICD) and a small
peptide such as P3 or Aβ in case of APP.
γ-Secretase-mediated RIP may activate, turn off or switch the
signaling properties of the transmembrane protein involved (Fig. 1).
For instance, RIP activates signaling pathways like Notch, by allowing
intracellular domains (ICD) to translocate to the nucleus where it incor-
porates into a transcriptional complex and regulates gene transcription
(Fig. 1A) [34]. Alternatively, RIP may turn off signaling events in which
the transmembrane anchored protein is responsible for signaling, and
the cleavage event terminates the signal. The cleavage of Deleted in
Colorectal Cancer (DCC), for instance, attenuates downstream sig-
naling (Fig. 1B) [35]. A third possibility is that the cleavage serves as
a switch between signaling modes with the uncleaved transmembrane
form activating one pathway at the membrane and the soluble ICD car-
rying out a different function in another cellular compartment (Fig. 1C).
This has been shown for various substrates including ErbB4 [36] and
APP [37].
4. The most prominent γ-secretase substrates
To date more than 90 substrates have been identiﬁed for
γ-secretase (reviewed in [38]). Although they are diverse in their
structure, localization and physiological functions, the majority of
these proteins share some common features. For instance, almost all
substrates are type-I transmembrane proteins. The only exceptions
identiﬁed so far are the polytopic membrane proteins glutamate recep-
tor GluR3 and polycystin-1 as well as the type-II transmembrane pro-
tein glucosaminyltransferase (GnT-V). Typically, they contain a large
ectodomain often including cell adhesion molecule-like domains, a
single-pass transmembrane domain and a cytosoplasmic tail frequently
capable of initiating or mediating intracellular signaling. Interestingly,
the γ-secretase-mediated RIP does not depend critically on recognizing
particular sequences in the transmembrane domains of its substrates
but rather on the size of the extracellular domain remaining after
(A) RIP activates signaling pathway (Notch)
(B) RIP inactivates signaling pathway (DCC)
(C) RIP switches signaling pathway (APP)
γ-secretaseMP
Notch
Delta/
Jagged
NICD
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PKA
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Fig. 1. γ-Secretase-mediated cleavage regulates signaling pathways. γ-Secretase-
mediated RIP which takes place after ectodomain shedding by a sheddase
(metalloproteinase (MP) or BACE) may activate, turn off or switch the signaling
properties of the transmembrane protein involved. (A) RIP activates signaling path-
ways such as Notch, by allowing intracellular domains (ICD) to translocate to the nu-
cleus where it incorporates into a transcriptional complex with CSL transcription
factors, p300 co-activator and histone acetyltransferase (HAT) and regulates gene
transcription [34]. (B) RIP turn off signaling events in which the transmembrane
anchored protein is responsible for signaling, and the cleavage event terminates the
signal. The cleavage of Deleted in colorectal cancer (DCC) attenuates downstream
cAMP/PKA signaling involved in neurite outgrowth [35]. (C) RIP serves as a switch
between signaling modes with the uncleaved transmembrane form activating one
pathway at the membrane and the soluble ICD carrying out a different function in an-
other cellular compartment. APP-CTF upon direct binding to Gαs activates cAMP/PKA
signaling pathway and regulates neurite outgrowth [37]. Upon γ-secretase cleavage,
the released APP-ICD binds to the histone acetyl-transferase Tip60 and Fe65 and
regulates gene transcription [202].
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of cleavage [39]. Also, γ-secretase substrates appear to function as sig-
naling proteins and regulate a wide variety of cellular events such as
cell fate determination, adhesion, migration, neurite outgrowth, axon
guidance or formation and maintenance of synapses. Interestingly,
many of these events are disrupted during neurodegeneration e.g. in
AD [40]. The most studied γ-secretase substrates are APP for its role in
AD, and Notch, a signaling molecule critically required in development
and cell fate determination in multicellular organisms. Therefore, a
brief description of both substrates is given in the following paragraphs.
4.1. Notch signaling pathway
By virtue of its determining role in development, the Notch signaling
pathway is probably one of the most extensively studied γ-secretase-
related functions in living organisms. Notch signaling is evolutionarily
conserved and plays a critical role in short-range communication during
the development of multicellular organisms, as it controls cell fate by
regulating cell proliferation, survival, positioning and differentiation
(reviewed in [41,34]). The importance of Notch signaling even extends
into adulthood where it regulates stem cell maintenance, binary cell
fate decisions, such as in the T- or B-lymphocyte lineage, and differenti-
ation in self-renewing organs. Notch proteins are a family of transmem-
brane receptors encoded by four distinct genes (Notch1–4) inmammals.
Binding of Notch receptor to one of its ﬁve Jagged/Delta ligands (Jag1
and Jag2 and delta-like 1 (Dll1), Dll3 andDll4) presented by neighboring
cells initiates a cascade of sequential proteolytic cleavage eventsmediat-
ed by α-secretase and γ-secretase, resulting in the release of the intra-
cellular domain of the Notch receptor (NICD) [34]. The pivotal role of
γ-secretase in activating the Notch cascade was shown in knock-in
mouse models, where a single point mutation V1744G near the trans-
membrane cleavage site in Notch1 sufﬁcient to inhibit intramembrane
proteolysis, phenocopied Notch1-deﬁcient mice [42]. After cleavage,
NICD translocates to the nucleus where it modulates gene expression
by binding to CBF1/RBPJk, suppressor of hairless Su(H), Lag-1 (CSL)
transcription factors. These interactions convert CSL from a transcrip-
tional repressor to an activator by displacing co-repressor and histone
deacetylases and recruiting histone acetyltransferases and co-activators
such as p300 [41]. Notch was originally discovered in Drosophila where
it induced “notched wings”. Its ﬁrst human homologue, NOTCH1, was
identiﬁed in T-cell acute lymphoblastic leukemia (T-ALL) patients with
the chromosomal translocation t(7;9) (q34; q34.3) found in less than
1% of T-ALLs [43]. The translocation breakpoints in this original case of
T-ALL were mapped within NOTCH1 on chromosome 9 and the T-cell
receptor beta locus on chromosome 7, resulting in the expression of a
truncated, constitutively active Notch 1 receptor [43].
Aberrant Notch signaling interferes with embryonic development
and has been detected in various human diseases including several
types of cancer. In some cancers including lymphocytic leukemia
and B-cell malignancies, constitutive activation of the Notch pathway
and increased levels of NICD are induced by molecular genetic alter-
ations including chromosomal translocation, point mutations and
chromosomal ampliﬁcation at the Notch receptor loci [44]. While
for a long time Notch has been thought to be solely a tumor promoter,
few studies provide now evidence that Notch acts also as tumor sup-
pressor. This is the case in squamous cell carcinomas of the head and
neck, lung and skin where loss-of-function mutations of Notch have
been identiﬁed [45–48].
Interestingly, not only the Notch receptor undergoes γ-secretase
mediated RIP, but also both its ligands, Delta and Jagged. Their shedding
is mediated by ADAM17 followed by γ-secretase mediated RIP, which
releases the respective intracellular C-terminal domains termed DICD
and JICD, in analogy to NICD [49,50]. Their ectodomain processing can
be stimulated by expressing Notch, as well as regulated by phorbol
ester/PKC activation. The fact that the soluble Delta ectodomain is not
an efﬁcient Notch activator [51,52] suggests that the ectodomain
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cell surface. Alternatively, the membrane tethered CTF of Jagged/Delta
may compete with Notch for γ-secretase processing. This scenario
would be particularly relevant during early lateral inhibition when
both Notch and its ligands are expressed in the same cell; competition
would then decrease the ability of a stimulated cell to release NICD
and therefore allow that particular cell to adopt its cell fate. Similar to
NICD, both JICD and DICD translocate to the nucleus where they affect
gene expression, including AP-1 for JICD [50]. While DICD was shown
to have a transcriptional activity [49], JICD does not and most probably
affects transcription by associating with a transcriptional activating
complex [50].
4.2. Amyloid precursor protein and Alzheimer's disease
Accumulation of β-amyloid (Aβ) plaques and hyperphosphorylated
tau bearing tangles in the brain of patients together with synaptic dys-
function and cognitive decline are hallmark features of AD. Biochemical
and genetic studies have identiﬁed Aβ as a trigger for AD pathogenesis.
Aβ is generated by the successive proteolytic cleavage of APP by BACE1
and γ-secretase [29].
Understanding the physiological functions of APP and its proteolytic
fragments as well as the regulation of its processing is of immediate rel-
evance for AD pathogenesis. One particularity of this substrate is that be-
side the amyloidogenic pathwaymentioned above, a non-amyloidogenic
pathway can take place. Herein, APP is ﬁrst cleaved by α-secretase
(mediated mainly through ADAM10 as well as ADAM17) to generate a
secreted N-terminal sAPP-α fragment. The remaining APP-CTF 83 is fur-
ther cleaved by γ-secretase to release a P3 peptide and APP intracellular
domain (AICD). In vitro and in vivo studies have shown important func-
tions for APP in various neuronal and synaptic processes. They can be
executed either as a full-length protein or as one of the processing prod-
ucts, often the soluble fragments, or the AICD but also the membrane-
tethered CTF [37], meaning that processing of APP is required and must
be highly regulated (review in [53]).
To add to the complexity, γ-secretase cleaves APP-CTF fragment at
multiple sites and likely successively (ε-, ζ- and γ-cleavage) [54]. Fol-
lowing the tripeptide processing model, γ-secretase cleaves within
the transmembrane domain of APP-CTF sequentially, N-terminally
directed, releasing three residues at each step [55,56]. The initial
ε-cleavage occurring at two major sites (Aβ48 or Aβ49) inﬂuences the
subsequent cleavages, meaning that Aβ48 is converted to Aβ42/38
and Aβ49 to Aβ43/40. At each step, the substrate is either further
processed or released from γ-secretase. This results in Aβ peptides of
different lengths, from 38 to 42 amino acids, the principal peptide
being Aβ40 and themost toxic being Aβ42 [57–59]. The region between
the γ- and ε-cleavage sites is shown to contribute to the interaction
scaffold with PSEN1 [20] and, interestingly, translocation prone pep-
tides mimicking this region selectively inhibit APP processing and Aβ
production but not Notch cleavage [60].
In general, overproduction of Aβ leads to neurotoxicity, synaptic
damage and eventually neuron loss [61]. In familial AD (FAD), muta-
tions in PSENs (1 & 2, http://www.molgen.vib-ua.be/ADMutations)
have shown to directly affect the processing of APPmostly by either in-
creasing the production of Aβ42 or decreasing the production of Aβ40
thereby affecting the ratio Aβ42/40 [54]. The molecular mechanisms
linking the different FAD mutations with the observed pathology are
not yet fully understood; what is becoming clear however is that all
FAD mutations cannot be explained with one common molecular
mechanism. Recently, in vitromeasurement of the kinetics of the activ-
ity of different FAD–PSENs demonstrated that not allmutations resulted
in a loss of function at the ε cleavage site. However, they all cause qual-
itative changes in Aβ proﬁles by variousmechanisms [59,62].Moreover,
besides APP, FADmutations affect also the cleavage of other substrates,
such as Notch [59,63], N-Cadherin [59,64], ErbB4 [59] and EphrinB
[65,66] and this even in distinct manners [59]. In addition to thesemutations, in late-onset AD changes in membrane trafﬁcking have been
suggested to affect APP processing and therefore membrane trafﬁcking
is emerging as a potent regulator of RIP [29,67,68].
Finally, efforts in the scientiﬁc community have led to the identiﬁca-
tion of a number of potential therapeutic targets for AD based on the
facts that they can modulate Aβ production without affecting Notch
cleavage. Such proteins can enhanceAβproduction by controlling the as-
sembly of γ-secretase, such as Rer1p ([24]; c.f. supra and infra) or redis-
tribution of the complex to membrane micro-domains as suggested for
the orphan G-protein coupled receptor GPR3 and β-arrestin [69,70]. Al-
ternatively they may help the interaction between APP and γ-secretase
as observed in case of γ-secretase activating protein (GSAP) [71].
In vivo diminished processing of APP upon genetic ablation of these
aforementioned proteins prevents plaque formation in AD mouse
models. Still, the role of this interaction has not been studied in a context
distinct from AD andmay be of relevance in other diseases and develop-
mental processes regulated by γ-secretase.
5. Role of γ-secretase in embryonic development
In mammals, there are 2 highly homologous PSENs, PSEN1 and
PSEN2. PSEN1 is ubiquitously expressed in all tissues, including embry-
onic and adult brain. Its expression is developmentally regulated and
changes in expression are associated with neuronal differentiation and
synaptogenesis [72,73]. Initial clues of its function within the Notch sig-
naling pathway have come from the C. elegans homolog sel-12, which
shares about 50% amino acid identity with PSEN1 and is a suppressor/
enhancer of LIN-12, a member of the LIN-12/Notch family of receptors
[74]. Throughout metazoan evolution, PSENs play essential roles in
development. Mice lacking either PSEN1 or both PSENs die perinatally
or during early embryonic development, respectively.More particularly,
PSEN1 knock-out mice exhibit severely abnormal development of
various tissues, consisting of a neuronal migration disorder, midline
defects of the body wall and defective somitogenesis [6,75–77]. Addi-
tionally, vascular lesions within the central nervous system cause
several hemorrhages into the parenchyma and lateral ventricle. PSEN1
plays also a critical role in neurogenesis, where it prevents neural pro-
genitor cells from differentiating into post mitotic neurons [75,78–80].
PSEN1 is also required for normal neuronal migration and cortical
lamination as well as survival of Cajal–Retzius neurons, with PSEN1-
deﬁcient mice presenting a pathology very similar to human type 2
lissencephaly [76]. It has been suggested that many of these lesions
and in particular the impaired somitogenesis and neurogenesis are a
consequence of disturbed Notch signaling in mice. However, it should
be noticed that PSEN1-deﬁcient mice differ as well in several aspects
from the Notch1 deﬁcient phenotype. While PSEN1−/− embryos are
viable until birth, Notch1 deﬁcient animals do not survive beyond em-
bryonic day E11 [81,82].
PSEN2 shares overall 63% amino acid identitywith PSEN1 and is pre-
dicted to have a very similar structure. It has been initially identiﬁed as a
functional PSEN1 homologue in C. eleganswhere both wild-type PSEN1
and PSEN2 could complement sel-12 function [83]. Unlike PSEN1-
deﬁcient animals, PSEN2-knockout mice are viable and fertile and de-
velop only mild pulmonary ﬁbrosis and hemorrhage with age [84].
Deﬁnitive evidences that PSEN2 and PSEN1 are functional homologues
andboth involved in theNotch signalingpathwaywere obtained in dou-
ble PSEN1/PSEN2-deﬁcient embryos, which closely resembled Notch-1
deﬁcient animals. Indeed, at E9.5, embryos were developmentally re-
tarded with delayed yolk sac vasculogenesis, absence of blood circula-
tion and posterior truncation [84,85].
APH1 is encoded by a single gene in C. elegans [86,87] and Drosoph-
ila melanogaster [88], whose loss of function causes overt Notch signal-
ing deﬁciencies. By contrast, mammalians harbor two APH1 (APH1a
and APH1b in humans) or three APH1 (APH1a, APH1b and its duplicated
gene APH1c in rodents [9]) genes. Because alternative splicing results in
two isoforms of APH1a, APH-1a long form (APH-1aL) and APH-1a short
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be found in humans and mice, respectively. This combined with two
PSENs results in up to 6 or 8 distinctly composedγ-secretase complexes
thatmay co-exist in tissues and cells [9]. The APH1a complexes are cru-
cial for Notch signaling during embryogenesis. Similar to Notch1 null
embryos, APH1a-/- embryos display defects in vascular morphogenesis
of the yolk sac, distention of the pericardial sac, underdeveloped ﬁrst
branchial arch and heart chambers, as well as kinks in the caudal part
of the neural tube, and mild defects in somite patterning, particularly
in the rostral somites [89,90]. APH1b and APH1c are highly similar
(96.3% identity at the nucleotide level) but interestingly are differential-
ly expressed. While APH1b is uniformly expressed in all tissues, APH1c
distribution is limited to the kidney and the testis [9]. In contrast to
APH1a−/−, APH1b–/–, APH1c–/– and APH1bc–/– homozygous mice are
viable and fertile [90] and present only a mild disturbance in prepulse
inhibition (APH1bc–/– mice) [91]. Furthermore, APH1bc deﬁciency
does not affect expression of Notch and its target genes. This agrees
well with the observation that Notch is predominantly expressed in
non-neuronal and neuronal precursor cells where APH1a but not
APH1b is expressed.
Finally, similar to PSEN1–/–/PSEN2–/– double KO and APH1a−/− single
KOmice, NCT−/− and PEN2−/− embryos die by embryonic day 10.5 and
E9.5, respectively, and exhibit several patterning defects, reminiscent of
Notch signaling defects. These include defects in somite segmentation
and in angiogenic vascular morphogenesis in the yolk sac, as well as
kinks in the neural tube, and distention of the pericardial sac [92,93].
The role of γ-secretase in embryonic development has been mostly
investigated in loss-of-function experiments.We recently reported that
a gain ofγ-secretase activity through loss of its negative regulator Rer1p
also affects normal embryonic development in zebraﬁsh. Because of
the selective high expression of Rer1p in ciliated cells and organs,
(morpholino-mediated) downregulation during development gives
rise to shortened cilia and impairment of their motile and sensory func-
tions [94]. Cilia, which are antennal organelles emanating from the sur-
face of most vertebrate cells, generate ﬂuid ﬂow (motile cilia) or
orchestrate signaling pathways including Hedgehog, PDGFRα and
non-canonical Wnt (primary cilia). Genetic defects in genes encoding
ciliary proteins gives rise to a class of human syndromes term
ciliopathies. In line with this, ciliary dysfunction caused by loss of
Rer1p and gain-of-function of γ-secretase activity in zebraﬁsh results
in developmental defects that resemble some clinical features of
human ciliopathies. Altogether, loss- and gain-of-function experiments
highlight the critical importance of balanced γ-secretase activity during
development [94].6. Role of γ-secretase in adulthood and disease
The investigation ofγ-secretase function in adulthood has been ham-
pered by the facts that the genetic inactivation of most γ-secretase com-
ponents causes prenatal lethal Notch phenotypes. To overcome early
lethality and study the function of γ-secretase in adulthood, groups
have turned towards mouse lines heterozygous/homozygous for one
or more components of γ-secretase that are compatible with survival
or towards conditional knock-out mice models.
In addition, the identiﬁcation of mutations in genes encoding
γ-secretase components in human diseases has enabled scientists to
explore and appreciate the broad range of physiological implications
of altering γ-secretase activities in health and disease development.
Such mutations have been so far described in ﬁve diseases including
frontotemporal dementia (FTD) and AD [95], acne inversa [96–98], di-
lated cardiomyopathy [99–102] and breast cancer [103](see Table 1).
Interestingly, in rare cases, mutations such as e.g. PSEN2 R62H have
been found in distinct diseases including AD, breast cancer and dilated
cardiomyopathy, suggesting a common underlying molecular mecha-
nism [101]. In contrary, so far, no overlapping mutations have beenidentiﬁed in acne inversa and AD that would indicate different implica-
tions of γ-secretase in those diseases.
6.1. γ-Secretase in adult brain
γ-Secretase plays a decisive role in the adult brain, ﬁrst recognized
upon discoveries of FAD mutations in the PSEN genes and since then
corroborated in various animal models and human diseases.
Conditional loss of both PSEN1 and PSEN2 orNCT in the cortex results
in progressive synaptic and memory impairment prior to age-
dependent neurodegeneration accompanied by increased levels of
hyperphosphorylated tau, another hallmark of AD [104–108]. In con-
trast, conditional PSEN1 knock-out mice exhibit only mild cognitive
deﬁcits in long-term spatial memory [108]. Interestingly, these deﬁcits
appear to be independent of the Notch signaling pathway [108,109].
PSENs are also essential for regulating neurotransmitter release during
synaptic transmission as shown in mice with speciﬁc deletion of both
PSENs in pre-synaptic (CA3) and post-synaptic (CA1) neurons of the
hippocampus [106]. Finally during adult neurogenesis, PSEN1 sustains
the proliferation of neuronal progenitor cells and restricts their differ-
entiation through EGF receptor and β-catenin pathways [110]. While
most of the neurological defects observed during embryonic develop-
ment have been ascribed to disturbed Notch signaling, it appears a dif-
ferent case during postnatal life where other γ-secretase substrates
come into play. For instance, Neuregulin-1 (Nrg1) may contribute to
the pharmacological and behavioral abnormalities in APH1bc-deﬁcient
mice that can be reversed by antipsychotic drugs [91]. Interestingly,
Nrg1, which is a prominent candidate gene associated with increased
risk for schizophrenia, and its receptor ErbB4 are both γ-secretase
substrates [91].
6.1.1. γ-Secretase in axon guidance
To ensure proper synaptic connections and plasticity (and therefore
brain function), the development of axonal and dendritic processes
must be tightly regulated in time and space. The neuronal wiring relies
on the coordination of at least two events: the secretion/presentation of
extracellular cues acting as guidance signals and the expression on the
moving neurons of the respective receptors, which eventually process
the signals [111]. γ-Secretase plays a potentially prominent role in reg-
ulating these processes asmanyof its substrates are axon guidancemol-
ecules or receptors [38,111]. The functional consequence of γ-secretase
cleavage are best deﬁned for the Netrin receptor, DCC, as its processing
is required for the sensitivity of axons to midline guidance cues
(Fig. 1B). Netrin-1 was identiﬁed as the ﬁrst guidance cue implicated
in neuronal guidance [112,113]. It is expressed in the ﬂoor plate of the
neural tube, to ﬁrst guide/attract commissural axons during nervous
system development [112,114]. When crossing the midline, the com-
missural axons lose their sensitivity to Netrin-1 and acquire responsive-
ness to repellents such as Slit, Ephrin and Semaphorin family members
[115]. Importantly, the expression and localization of these guidance
cues and receptors is exquisitely tailored to allow growth cones to rap-
idly switch their responsiveness at speciﬁc times and places throughout
development. DCC-CTF stimulates neurite outgrowth by orchestrating
signaling pathways including cAMP/PKA and protein kinases [35]
which become later on abrogated through γ-secretase cleavage that
releases the DCC intracellular domain. As such, in cultured neuroblasto-
ma, preventing γ-secretase activity results in the accumulation of
DCC-CTF and enhanced neurite outgrowth (Fig.1B) [35,116]. Similarly,
overexpression of a myristoylated form of DCC causes axon growth de-
fects by activating downstream kinases [117]. Finally, overexpression of
a DCC-CTF variantwhich cannot be cleaved byγ-secretase causesmotor
neurons to remain responsive to Netrin-1. They are unable to switch
and respond to repellent neurons and therefore cannot exit the neural
tube [117]. These ﬁndings are further supported by the observation of
aberrant axonal growth in a PSEN1 mouse mutant generated from a
mouse ENU mutagenesis screen [118]. In these so-called Columbus
Table 1
Non-exhaustive list of diseases related to a defect in γ-secretase mediated signaling pathway.
Organ Disease and development Mutations of γ-secretase components in diseases Potential substrates or molecular mechanism
Brain • Neurodegeneration (AD, FTD) [95]
• Cognitive defects [104–108]
• Adult neurogenesis [110]
• Axon guidance [118]
• Synaptogenesis [122,127–129]
• PSEN1 (AD, FTD) [95]
• PSEN2 (AD, FTD) [95]
• APP [119]
• Neuregulin1 [91]
• DCC [35,116,118]
• EphrinB2 [122]
• Neuroligin [127,128]
• EphrinA4 [129]
Kidney • Nephrogenesis [131,132] • Notch [133]
• Polycystin-1 [142]
• Fibrocystin/polyductin [149]
Skin • Hair follicle development [150]
• Acne inversa (AI) [96,155]
• PSEN1 (AI) [96,155]
• NCT (AI) [96,155,200]
• PEN2 (AI) [96,155]
• Notch [150]
Immune system • Splenomegaly [151,152,161]
• Autoimmune disease [152,161]
• T cell development [162,163]
• B cell development [164]
• Notch [165]
• HLA-A2 [201]
• IL-1R2 [171]
• IL-1R1 [172]
• LRP1 [173]
• CX3CL1 [174]
• CXCL16 [174]
• CD46 [175]
Heart vascular • Cardiac morphogenesis [85,178]
• Calcium homeostasis [100]
• Dilated cardiomyopathy (DCM) [100]
• Diabetic retinopathy [188,189]
• Age-related macular degeneration [191]
• PSEN1 (DCM) [99,100]
• PSEN2 (DCM) [99]
• Notch [101]
• Ca2+ [100]
• IGF-1R [177]
• ErbB4 [177]
• VEGFR [177]
• APP [177]
Cancer • Hyperplasia and skin cancer [151–153,156]
• Breast cancer[103]
• Glioma [193]
• T-LL [166]
• Leukemia [169]
• PSEN2 (breast) [103]
• NCT (leukemia) [169]
• E-cadherin [192]
• Notch [44]
• Nrg1/Erb4 [193]
• EpCAM [195]
• β-catenin [153]
AD, Alzheimer's disease; APP, Alzheimer precursor protein; FTD, frontotemporal dementia; AI, acne inversa; DCM, dilated cardiomyopathy.
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response to netrin-1, due to accumulation of DCC-CTF [118]. As a conse-
quence these mice present aberrant growth of some motor axons into
the ﬂoor plate at the midline instead of exiting laterally at their normal
ventral root sites. APP was shown recently to be also part of the DCC re-
ceptor complex which mediates netrin-1-dependent axon guidance
[119]. APP interacts with DCC in the presence of netrin-1 and enhances
netrin-1-mediated DCC intracellular signaling, such as MAPK activation
[119]. Finally, netrin-1 binding to APP regulates its processing resulting
in lower Aβ secretion [120].
Bidirectional signaling through anotherγ-secretase substrate, name-
ly the ephrinB ligand and its EphrinB receptor (EphB), is also important
for several neuronal functions such as axon guidance, neuronal plastici-
ty, spine maturation and synaptogenesis [65,66,121,122]. For instance,
binding of the receptor EphB to its ligand ephrinB stimulates ephrinB
processing by γ-secretase. Liberation of ephrinB2-ICD activates Src sig-
naling pathway which in turn phosphorylates ephrinB2 ligand [65].
Phosphorylated ephrinB enables the binding to Grb4 which will further
modulate spine morphogenesis and synapse formation [65,123]. In
addition, phosphorylation of the ligand prevents its processing and
thereby creates an inhibitory feedback mechanism. Importantly, this
pathway was shown to be inhibited by PSEN1 FAD mutations [65,122].
Overall, it becomes clear that disturbance of γ-secretase activity
results in abnormal axonal guidance, contributes to defect in the
maintenance and repair of neuronal circuits and thereby may be po-
tentially involved in the development of AD [111]. Future studies on
the regulation of guidance signaling pathways by γ-secretase could
provide new insight into the molecular relationships between neural
development and degeneration.
6.1.2. γ-Secretase at the synapse
The nervous system also depends on proper neuronal communica-
tion that takes place at the synapse. Formation and maintenance of
the synaptic structure is a dynamic process that requires bidirectionalinteraction between pre- and postsynaptic elements [124]. Under-
standing how (altered) γ-secretase activity may modulate this is of
potential value to AD. Also, it is generally appreciated that synaptic
dysfunction and in particular defects in neurotransmitter release
precedes neurodegeneration [125]. Several cell adhesion molecules,
some of which are γ-secretase substrates, are present at the synapses
and are crucial for their function and organization. One well charac-
terized synaptic cell-adhesion molecule is the receptor neuroligin
(NLG). NLG is expressed at the post-synaptic membrane and binds
to its presynaptic ligand neurexin (NRX) to initiate signaling across
the synapse. Mutations in these proteins have been linked to distinct
cognitive diseases, such as autism spectrum disorders, Tourette's syn-
drome, schizophrenia and learning disability [126]. The levels of NLG
within the synaptic membrane are presumed to directly modulate
synaptic function. Interestingly, recent ﬁndings suggest that process-
ing of NLG by ADAM10 [127] or metalloproteinase 9 [128] followed
by γ-secretase regulates its presence at the synapse [127]. NLG pro-
cessing was shown to be stimulated by NMDA receptor and the solu-
ble NRX fragment. Cleavage of NLG results in lower synaptic strength
and reduces presynaptic release without affecting the postsynaptic
structure and function [128]. In addition, by analyzing the amount of
NLG ectodomain shedded fragment in the aging mouse brain, Peixoto
and co-authors showed that NLG processing is upregulated during
early stages of development [128], but it remains to be deﬁned if NLG
processing is involved in synaptic maturation during development.
Inoue and co-authors [129] found that γ-secretase-mediated
EphrinA4 receptor (EphA4) processing regulates the morphogenesis
of dendritic spines. This EphA4-cleavage is disrupted by FAD muta-
tions in PSEN1, raising the possibility that abnormal processing of
EphA4 may contribute to AD pathogenesis or affect the maintenance
and repair of neuronal circuits [129]. The authors also showed that
the processing is enhanced by synaptic activity [129]. High levels of
EphA4 ICD were shown to increase the number of dendritic spines
via activation of the Rac signaling pathway, consistent with the fact
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6.2. γ-Secretase and kidney: Notch and beyond
γ-Secretase deﬁciency in the kidney leads to severe defects. PSEN1,
PSEN2-double knock-out embryos present no comma- or S-shaped
bodies, as well as no mature glomeruli [131]. Additionally, treatment
of cultured isolated mouse embryonic metanephroi with γ-secretase
inhibitor caused a severe deﬁciency in proximal tubules and glomeruli
[132]. Although both studies suggested that the Notch pathway may
be the underlying mediator for PSEN activity in kidney development,
up to three γ-secretase substrates including Notch, polycystin-1 and
ﬁbrocystin/polyductin are recognized for their renal functions.
Notch signaling molecules are expressed throughout kidney de-
velopment and are involved in pronephros development in Xenopus,
mice and zebraﬁsh (reviewed in [133]). In Xenopus, blocking Notch
signaling upon injection with a dominant negative CSL converts tubu-
lar cell fate to ductal cell fate [134]. Mice with a hypomorphic allele
for Notch2 or mice with a targeted deletion in the kidney showed
hypoplastic kidneys with glomerular defects [135]. Additionally in
the zebraﬁsh, Notch signaling controls the formation of single versus
multi-ciliated cells (MCC) in the pronephros, likely required for
chemosensing/signal transduction and ﬂuid propulsion, respectively
[136]. Loss- and gain-of-function of Notch signaling pathway compo-
nents has been associated with many renal disorders. Mutations in the
genes encoding for Jagged1 and Notch2 are responsible for Alagille syn-
drome (AGS), an inherited autosomal dominant disease characterized
bymulti-organ dysfunction and awide spectrum of renal abnormalities
[137]. Renal cysts are also observed in Hajdu Cheney and serpentineﬁb-
ula polycystic kidney syndromes that display mutations in Notch2
[138,139]. The expression of Notch receptors and ligands is strongly
decreased in the mature kidney, but abnormal Notch activation is
observed in different models of acute and chronic kidney disease in-
cluding diabetic nephropathy, focal segmental glomerulosclerosis and
disease associated with ﬁbrosis [133]. For instance, conditional over-
expression of NICD in podocytes or in tubular epithelial cells results in
glomerulosclerosis or tubulointerstitial ﬁbrosis, respectively [140,141].
Furthermore, genetic deletion of a Notch transcriptional partner (Rbpj)
speciﬁcally in podocytes or proximal tubules or pharmacological inhibi-
tion of Notch signaling using γ-secretase inhibitors showed protective
effects in rats with proteinuric kidney diseases or against ﬁbrosis devel-
opment, respectively [140,141]. Hence, Notch is a key regulator of kidney
development, repair and injury and both loss- and gain-of-function re-
sult in kidney diseases.
Polycystin-1 (PC1), which has been recently discovered as a novel
γ-secretase substrate [142], plays also an essential role in kidney develop-
ment and disease. Importantly, the gene encoding PC1 (Pkd1) is mutated
in 85% of the cases of autosomal-dominant polycystic kidney disease
(ADPKD), a common genetic disease producing ﬂuid-ﬁlled renal cysts
that disrupt the normal tubular architecture and that can ultimately
lead to kidney failure [143]. The other 15% of the cases result frommuta-
tions in the gene encoding polycystin-2 (Pkd2), a non-selective calcium
permeable cation channel that interacts and forms a complex with PC1.
PC1 is an atypical γ-secretase substrate by the fact that it is composed
of 11 TMDs, while almost all γ-secretase substrates are type-I transmem-
brane proteins. To be fully functional PC1must undergo N-terminal auto-
catalytic cleavage in the secretory pathway [144] which could be seen as
the functional equivalent of ectodomain shedding in classical substrates.
Knock-in mice expressing the non-cleavable PC1 protein develop severe
polycystic kidney disease after birth [145] and so do missense mutations
in humans. Later, the PC1 C-terminal tail (PC1-CTT) is released by
γ-secretase mediated RIP and translocates to the nucleus. Reduced ﬂuid
ﬂow in the kidney increases PC1 cleavage and nuclear translocation,
suggesting that it may initiate cellular responses to mechanical stress
[146]. In agreement with this, once in the nucleus PC1-CTT regulatesseveral signaling pathways including Wnt and activator protein-1
(AP-1) [146]. Additionally it inhibits TCF and CHOP by disrupting their in-
teraction with p300. Importantly, PC1-CTT is sufﬁcient to restore normal
tubular morphology and dorsal axis curvature in cells or zebraﬁsh null
for pkd1 or treated with γ-secretase inhibitor, respectively, thereby infer-
ring thatγ-secretase-mediated cleavage of PC1 plays an obligate role in at
least a subset of its physiological functions [142].
The third γ-secretase substrate involved in renal function, ﬁbrocystin/
polyductin is the gene product of the human autosomal recessive poly-
cystic kidney disease gene (ARPKD), PKHD1. Patients with defects in
this gene develop severe cystic kidney disease along with defects in the
lung, pancreas, and liver [147,148]. Fibrocystin is a large type-I transmem-
brane protein that is predicted to function either as a receptor or ligand
but there is no evidence so far. Moreover, it is suggested to maintain the
planar cell polarity (PCP) in the kidney. The mechanism by which muta-
tions in PKHD1 produce ARPKD is currently not known. Fibrocystin
which localizes to cilia and centrosomes in mammalian cells undergoes
shedding by ADAM metalloproteinases followed by the release of an
ICD fragment by γ-secretase [149]. However, so far no nuclear function
to the ﬁbrocystin ICD has been attributed and further studies are required
to evaluate the impact of γ-secretase cleavage on the development of
ARPKD.
6.3. γ-Secretase function in skin development and disease
Both human and animal data functionally support a role for
γ-secretase in skin development and skin cancer. First, PSENs are re-
quired during skin development to maintain the differentiated cellular
identity within the hair follicle and their absence leads to the conver-
sion of hair follicles into epidermal cysts [150]. Yet, they are not in-
volved in skin patterning or cell fate acquisition of the hair follicle as
shown in conditional knock-out mice (msx2-cre driven ablation of
PSEN1/PSEN2). These mice also show a severely hyperplastic epidermis
and the absence of sebaceous glands. Additionally, partial loss of
γ-secretase activity (of at least 50%) in skin leads to the development
of epidermal hyperplasia and skin tumors including squamous cell car-
cinomas (SCC) in adult mice. This was observed in many different
mouse models including Nct+/− and Nct+/−/PSEN1+/− knock-out
mice [151], PSEN1+/−PSEN2−/− mice older than 6 months [152] and
PSEN1 knockout mice that are rescued through neuronal expression of
a human PSEN1 transgene [153].
In human, heterozygous mutations of the γ-secretase genes PEN2,
PSEN1 and NCT were recently reported in acne inversa (AI, also called
hidradenitis suppurative), a chronic inﬂammatory skin condition that
presents with comedones, painful nodules, abscesses and sinus tracts in
apocrine gland-bearing areas [154]. Longstanding disease can result in ﬁ-
brosis, dermal contractures, scaring, formation of ﬁstulae and rarely ma-
lignant transformation to SCC. To date, 17 NCT, 3 PEN2 and 1 PSEN1
mutations have been reported in eleven kindreds and four sporadic
cases, of which three are nonsensemutations, seven result in frameshifts,
seven in altered splicing and four are missense mutations (reviewed in
[155]). Haploinsufﬁciency of the γ-secretase component genes suggests
that critical levels of γ-secretase activity are required to maintain skin
homeostasis. This is supported by the ﬁndings that a number of in-
dividuals involved in the clinical trial of the γ-secretase inhibitor
Semagacestat for AD reported cutaneous side effects and an increased
risk of skin cancer [156].
Most of the skin developmental defects observed in γ-secretase-
deﬁcient mice have been related to Notch signaling pathway defects.
Indeed, compound loss of the different Notch receptors phenocopies
loss of γ-secretase in hair follicles therefore inferring that Notch pro-
teolysis is a major signaling function of γ-secretase in skin [150]. In-
terestingly a recent study showed that Notch and PSEN2 are present
in ciliary structures of suprabasal epithelial cells and that the cilium
may function directly in ﬁne-tuning the Notch-regulated balance be-
tween proliferation and differentiation in developing skin [157].
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contributes to the skin tumor phenotype. This was previously thought
to relate to a γ-secretase independent function of PSEN1 where direct
interaction of PSEN1withβ-catenin or N- and E-cadherins at the adher-
ent junction regulates β-catenin stability and downstream signaling
[153,158]. However, rescue of this phenotype is possiblewith a synthet-
ic mutant of PSEN1 that disrupts the cadherin/catenin interaction with
PSEN1 but maintains γ-secretase-mediated Notch signaling [159]. Also,
because the interaction between PSEN1 and β-catenin concerns only
themembrane-associated pool, the absence of PSEN1may have little ef-
fect on the soluble cytoplasmic pool of β-catenin,which ismore directly
regulated by GSK/Axin/APC signaling. Therefore, these skin tumors are
now thought to be another manifestation of the many different defects
caused by deﬁcient Notch signaling in PSEN1 knockout mice. This is in
agreement with the ﬁndings that Notch1 acts as a tumor suppressor
in skin via regulation of β-catenin signaling [160].
6.4. γ-Secretase in immune system homeostasis and disease
The phenotypic characterization of several in vivoγ-secretase defec-
tive mouse models has revealed strong links between γ-secretase and
the immune system. For instance, reducing levels of γ-secretase by at
least 30% (Nct+/− and Nct+/−PSEN1+/−mice) increases risk for devel-
opment of splenomegaly characterized by hyperproliferation of
granulocytes and reduction of T-cell populations [151]. Interestingly
this phenotype is age-dependent as enlarged spleens were only ob-
served in mice older than 15 months. Adult PSEN1−/+PSEN2−/− mice
also develop splenomegaly with granulocyte inﬁltration in addition to
a serious autoimmune phenotype characterized by B-cell dominated
inﬁltrates, hypergammaglobulinemia with immune deposits in tissues
including skin and kidney, high titer nuclear autoantibodies and in-
creased CD4+/CD8+ ratio [152,161].
Mice with conditionally deleted PSEN genes in developing T cells
(cd4-Cre-PSEN1Δ/Δ,PSEN2−/−) have a defective CD4+ T cell develop-
ment associated with impaired TCR signaling as a consequence of
poor positive selection of thymocytes. Re-expression of NICD rescues
this phenotype thereby inferring a role of PSEN-dependent Notch
signaling in thymocyte development [162]. Moreover these condi-
tional PSEN KO mice displayed a signiﬁcant decrease in the number
of CD8+ cell on the periphery in addition to having CD4+CD8+
double-positive cells resistant to anti-CD3-induced apoptosis [163].
PSENs also play a role in B-cell function as PSEN-deﬁcient B cells
(CD19-cre, PSEN1Δ/Δ, PSEN2−/−) displayed a defective marginal
zone and T2 B cell development that is reminiscent of observations
in Notch2-deﬁcient and RBPJ-deﬁcient B cells [164]. Additionally,
they display deﬁcits in signal transduction events including lipopoly-
saccharide (LPS)-induced proliferation and anti-IgM-mediated calci-
um ﬂux. These defects are likely to be independent of defects in
Notch activation because both were normal in B cells lacking RBPJk.
Most of the hematopoietic defects observed in γ-secretase defective
animals have been ascribed to the Notch signaling pathway, being con-
sistent with the fact that Notch is required for proper hematopoiesis.
More particularly, Notch1 signaling is crucial for T-cell speciﬁcation in
early hematopoietic progenitors, namely the T- versus B-cell lineage
choice in early hematopoietic progenitors, by promoting their prolifera-
tion, differentiation and survival in the thymus (for review, see [165]).
Notch also plays a clear pathological role in T-cell lymphoblastic leuke-
mia (T-LL) in which the majority of human andmurine tumors have ac-
quired mutations that lead to aberrant increases in Notch signaling
[166]. For instance, Notch1 gain-of-function mutations have been found
in roughly 60% of primary human T-LL [167]. Most Notch1mutations in
human T-LL fall either into the heterodimerization (HD) domain or
into the C-terminal PEST (polypeptide enriched in proline, glutamate,
serine and threonine) domain. HD domain mutations are found in 40
to 50% of T-LLs patients and usually consist of point mutations or small
in-frame insertions or deletions. They destabilize Notch sufﬁciently topermit ligand-independent metalloproteinase shedding, albeit still re-
quiring γ-secretase activity [168]. The PEST domain targets the protein
for degradation through the proteasome pathway and thereby modu-
lates the half-life of NICD in the nucleus [34]. Hence, T-LL associatedmu-
tations or deletions of the PEST domain accentuate Notch activity by
increasing NICD half-life, a process independent of γ-secretase activity
(see for review [165,166]). Interestingly, few loss-of-function muta-
tions in the Notch signaling pathway including a null mutation in
NCT (NCTA433T) have been identiﬁed in leukemia patients, suggesting
again that Notch acts not only as a tumor promoter but also as a tumor
suppressor gene in leukemia [169].
Additional γ-secretase substrates play as well roles in the develop-
ment and function of hematopoietic cells; albeit the direct function of
some of their cleavage products has remained elusive. These include
(1) HLA-A2 (human leukocyte antigen-A2), a major histocompatibility
complex class I protein with primary functions in T-cell development
and initiation of immune cell response [170]; (2) IL-1R2 (interleukin-1
receptor type 2) [171] and (3) IL-1R1 that play important roles in innate
immunity and inﬂammatory responses and Il-1R1 cleavage potentiates
downstream MAPK activation [172]; (4) LRP1 (lipoprotein receptor-
related protein 1) whose cleavage product restricts LPS-stimulated pro-
duction of proinﬂammatory cytokines by macrophages [173]; (5) the
transmembrane chemokines CX3CL1 and CXCL16 [174]; as well as (6)
CD46 whose cleavage is important for T cell activation, proliferation
and cytokine production [175].
6.5. γ-Secretase functions in the cardiovascular system
Important developmental processes like vasculogenesis, angiogene-
sis [90,176] (for review [177]) and cardiac morphogenesis [85,178]
also do not escape from a functional involvement of γ-secretase activi-
ties. PSEN1, APH1a and PEN2 knockout mice show abnormal blood
vessel development and a disorganized vascular system [90,92,176].
Up-regulation of PSEN2was also reported in a retinal model of retinop-
athy of prematurity [179]. This elevation was due to an increased
binding of HIF-1-DNA to the PSEN2 gene promoter.
Finally, mutations of PSEN1 and PSEN2 genes have been described
in dilated cardiomyopathy (DCM) patients [99,100,102]. DCM is char-
acterized by ventricular enlargement and contractile dysfunction
with normal left ventricular wall thickness. Since the mutations de-
scribed in this pathology were already listed as FADmutations, Gianni
and coworkers have hypothesized that protein aggregation could be
the leading cause of the disease as in AD. The presence of ﬁbrillar
and oligomeric assemblies in the hearts of DCM patients suggest ab-
normal protein aggregation and could explain the alteration on
Ca2+ homeostasis [100]. Alternatively, using Drosophila as a model
to study the role of PSEN in heart function, Li and co-authors have
shown that cardiac dysfunction resulted from aberrant calcium chan-
nel receptor activities and disturbed Wnt signaling transduction due
to affected Notch processing [101].
While most of the effects of γ-secretase activity on the cardiovas-
cular system have been associated to its substrate Notch, which is an
important modulator of endothelial behavior, other substrates like
VEGFR, ErbB4, cadherin and IGF1R also contribute signiﬁcantly.
For instance, VEGF signalingwhich plays a critical role in angiogenesis
is modulated by γ-secretase. Upon binding to its ligand VEGF, VEGFR-1
gets processed by γ-secretase generating a VEGFR-1-ICD fragment that
acts as a negative regulator of VEGFR-2-mediated neovascularization
[180]. Also, upon pigment epithelium-derived factor (PEDF) treatment,
γ-secretase is actively transported to the plasma membrane which in-
duces its activity and thereby prevents angiogenesis in microvascular
endothelial cells.
Upon binding to epidermal growth factor (EGF), its receptor ErbB4
undergoes γ-secretase-mediated processing resulting in the release
and nuclear translocation of the ErbB4-ICD fragment where it regu-
lates transcription promoting migration and proliferation, although
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also been shown that neuregulin-2 binding to ErbB4 prevents angio-
genesis [183].
In the case of E- andN-cadherin, their processingwill result in disso-
ciation of the adhesion complex required for proper cell–cell junctions
[184–186]. In the case of the blood vessel, the vascular endothelial
(VE)-cadherin regulates the permeability and prevent leakage [187].
However, γ-secretase-mediating processing of VE-cadherin remains to
be reported.
IGF-1 (insulin-like growth factor-1) is a pro-angiogenic factor that
signiﬁcantly contributes in aberrant neovascularization associated
with diabetic retinopathy [188,189]. Its receptor, IGF-R has been re-
cently reported to be a substrate of γ-secretase although the down-
stream signaling pathway initiated by its cleavage product remains
to be elucidated [190].
Finally, as Aβ has been reported to be present in extracellular
deposits called Drusen which are a hallmark of age-related macular
degeneration (AMD), APP appears to also participate to diabetic reti-
nopathy and AMD in the eye [191].
6.6. Role of γ-secretase in cancers
In addition to the critical roles of γ-secretase in skin cancer and
leukemia described in previous paragraphs, two FAD mutations in
PSEN2, namely R62H and R71W, have been identiﬁed in breast cancer
patients [103]. To and coworkers showed that both mutations alter
the stability of PSEN2 and therefore may induce a loss-of-function ef-
fect. Although the role of these mutations in FAD is still unclear, both
mutations do not affect Aβ(42/40) ratio but rather alter Notch signal-
ing as shown in C. elegans and promote cell growth inhibition in
mouse embryonic ﬁbroblasts [103]. Besides FAD mutations, up-
regulation of γ-secretase components has also been reported in can-
cer. NCT levels were shown to be elevated in invasive breast cancer
[192], PSEN2 in brain tumors [193] and PSEN1 in human malignant
melanoma [194]. Liu and coworkers demonstrated that in malignant
glioma tissue, upregulation of PSEN2was due to its promoter demeth-
ylation. Consequently, downregulating the expression of either NCT
or PSEN2 prevented the development of cancer.
Besides hyperactivation of the Notch signaling described in cancer
cells, E-cadherin cleavage by γ-secretase releases cell–cell contact
and promotes invasion and metastasis. Therefore downregulating
γ-secretase prevents E-Cadherin cleavage, dissociation of the cell–
cell contact and metastatic cell transformation [192].
EpCam (epithelial cell adhesion molecule, CD326), another
γ-secretase substrate, mediates epithelial-speciﬁc intracellular cell-
adhesion. Its overexpression in most carcinomas has been proposed as
a potent protein marker in oncology [195]. Recently, the molecular
mechanism of EpCam in oncogenesis was demonstrated and involves
the γ-secretase mediated processing of EpCAM and subsequent release
of an EpCam-ICD fragment that forms a nuclear complex with FHL2,
β-catenin and Lef-1 to activate gene expression [196].
7. Concluding remarks
Since its discovery more than ﬁfteen years, the complex biological
implications of γ-secretase activity are becoming increasingly evident.
Because of its many substrates, γ-secretase is involved in vital physio-
logical processes in health and unfortunately also in diseases. Therefore,
understanding the proper regulatorymechanisms of its activity for each
substrate in its specialized cell type is highly relevant to understand the
molecular mechanism of diseases and develop novel therapeutical
approaches. Especially how mutations in γ-secretase can either lead
to a neurodegenerative disease or a cancer needs to be addressed.
Furthermore, as previously mentioned up to six different γ-secretase
complexes are present in humans and eight in rodents and it is becom-
ing increasingly evident that different complexes have heterogeneousbiochemical and physiological properties. Therefore, understanding
the nature of each γ-secretase complex is becoming highly signiﬁcant
as their diversity become apparent but far from understood. On the
other hand, while the list ofγ-secretase substrates is constantly growing,
the function(s) of most of them are at most partially known or currently
under investigation. While at ﬁrst one needs to understand the critical
function of each substrate in health and disease by using various ablation
methods in animal models, we also need to fully comprehend the phys-
iological consequences of its processing by γ-secretase. Approaches sim-
ilar to the Val1744 mutation knock-in in Notch that phenocopies
Notch-deﬁciency are therefore needed for other substrates.
The tremendous progress made in the past ﬁfteen years has as
well boosted major interests from academic and pharmaceutical in-
dustry to ﬁnd treatments and to maximally exploit γ-secretase as a
relevant drug target [197]. We are likely coming into an era in
which, after multiple failed clinical trials for AD, γ-secretase inhibi-
tors are now entering clinical trials for treatment of distinct diseases.
More particularly, the inhibitor R04929097 is currently used in phase
I/II clinical trials to see how well it works in treating young patients
with relapsed or refractory solid tumors, CNS tumors, lymphoma,
or T-cell leukemia (http://clinicaltrials.gov/show/NCT01088763). De-
spite intense drug development programs, no therapeutic drugs have
yet reached the clinic for AD mainly caused by the great danger of cre-
ating unexpected side effects which are not fully understood. Certainly,
a better understanding on the heterogeneity of γ-secretase complexes
functionwill help in developing substrate speciﬁc inhibitors ormodula-
tors. As well, another hope of therapy aims at further developing
γ-secretase modulators which instead of blocking its activity shift it in
order to produce shorter Aβ peptides without affecting the Notch sig-
naling pathway [71,198,199].
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